Skip to content
Business
Prognosis

Pfizer Covid Booster for Children 5 to 11 Gets FDA Authorization

A healthcare worker administers a dose of the Pfizer-BioNTech Covid-19 vaccine to a child in Philadelphia.

A healthcare worker administers a dose of the Pfizer-BioNTech Covid-19 vaccine to a child in Philadelphia.

Photographer: Hannah Beier/Bloomberg

Pfizer Inc. and BioNTech SE gained US emergency use authorization for their Covid vaccine booster shot for kids ages 5 to 11, a move to bolster protection in school-aged kids as contagious omicron subvariants spread across the country.

The Food and Drug Administration clearance allows the use of the booster at least five months after children receive the second of their first two shots. The companies submitted data to the agency in late April showing the third shot could bolster antibodies in the age group.